Browsing by Author "Kalkan, Serpil"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Article Citation - WoS: 0Citation - Scopus: 0The Ameliorative Effects of Hesperidin in Rats Developed Hepatotoxicity With Deltamethrin(Mashhad Univ Med Sciences, 2025) Savaş, Hasan Basri; Sozen, Mehmet Enes; Ayan, Ilknur Cinar; Savas, Hasan Basri; Cuce, Gokhan; Kalkan, Serpil; Department of Basic Medical Sciences / Temel Tıp Bilimleri BölümüObjective(s): Deltamethrin (DLM) is a widely used insecticide in agriculture; however, exposure to it can lead to serious health problems. This study aimed to evaluate the protective effects of hesperidin (HSP), a natural antioxidant, against DLM-induced liver toxicity. Materials and Methods: Thirty-two male Wistar Albino rats (250-300 g, 4 months old) were divided into four groups. The control group received 1 ml of corn oil via oral gavage for 30 days. The DLM group received 1.28 mg/kg DLM in corn oil for 30 days. The DLM+HSP 100 mg/kg and DLM+HSP 300 mg/kg groups received 1.28 mg/kg DLM followed by 100 mg/kg or 300 mg/kg HSP in distilled water, respectively, 30 min after DLM administration for 30 days. Liver tissues were examined histopathologically. Masson's trichrome staining and PCR assessed fibrosis. Caspase 3 and 9 expressions in liver tissues were determined by immunohistochemistry and PCR. Biochemical analyses were conducted on serum samples. Results: HSP supplementation led to a dose-dependent decrease in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. DLM exposure decreased antioxidant capacity, while HSP supplementation increased it dose-dependently. Histopathological evaluations showed increased liver damage in the DLM group, while HSP administration reduced liver toxicity. Masson's trichrome staining and analysis of collagen I (COL1A1) and collagen III (COL3A1) gene expression revealed increased fibrosis in the DLM group, which was attenuated with HSP treatment. Conclusion: The potential prevention of DLM-induced liver toxicity and apoptosis by HSP may be an alternative protective strategy.Article Citation - WoS: 1Citation - Scopus: 2Protective Effect of Astaxanthin on Histopathologic Changes Induced by Bisphenol a in the Liver of Rats(Univ Agriculture, Fac veterinary Science, 2024) Savaş, Hasan Basri; Gultekin, Burcu; Ayan, Ilknur Cinar; Savas, Hasan Basri; Cuce, Gokhan; Kalkan, Serpil; Department of Basic Medical Sciences / Temel Tıp Bilimleri BölümüBisphenol A (BPA) has several potential uses, including in polycarbonate plastics and epoxy resins, which could expose humans to it. Recognized for its hepatotoxicity and ability to accumulate in organs. We prompted this study to explore the hepatoprotective potential of astaxanthin (ASTX), an antioxidant against BPA toxicity. We used 32 male Wistar Albino rats and randomly assigned them as: Control, Sham (olive oil), BPA, and BPA+ASTX. At the end of the experiment, Native Thiol, Total Thiol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured in serum samples. Histopathological scoring was performed to evaluate the changes caused by ASTX in the liver. Caspase 3 and caspase 9 expression in liver tissues was demonstrated immunohistochemically and by PCR. Collagen I (COL1A1) and collagen III (COL3A1) mRNA levels were measured by PCR in the tissue samples. The BPA group showed elevated AST and ALT with decreased Thiol levels. ASTX administration reversed these changes as observed by reduced AST and ALT levels and increased Thiol levels. Histopathology indicated increased liver damage and fibrosis in the BPA group which were alleviated in the BPA+ASTX group. Gene expression analyses revealed upregulated COL1A1 and COL3A1 in BPA, which was downregulated with ASTX. Immunohistochemistry and PCR confirmed BPA-induced caspase 3 and caspase 9 expression, which were attenuated by ASTX. This study underscores ASTX's hepatoprotective efficacy against BPA-induced hepatotoxicity which ultimately attributed to its antioxidant and antiapoptotic properties. Consequently, ASTX emerges as a promising therapeutic agent for preventing and treating BPA-related liver diseases.